Relay Therapeutics Announces Proposed Public Offering of Common Stock

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Relay Therapeutics Announces Proposed Public Offering of Common Stock

Goldman Sachs Reinstates Relay Therapeutics (RLAY) at Buy

September 9, 2024 4:47 PM EDT

Goldman Sachs analyst Salveen Richter reinstates coverage on Relay Therapeutics (NASDAQ: RLAY) with a Buy rating and a price target of $20.00.

The analyst comments "Given positive Ph2 data of selective PI3K inhibitor RLY-2608 + fulvestrant in PI3K-mutated HR+/HER2- breast cancer and planned Ph3 initiation in 2025, we reinstate RLAY with a Buy rating and $20 price... More